Status:
RECRUITING
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were ide...
Detailed Description
This study is a prospective study to establish an early diagnosis model for the diagnosis of liver cancer based on peripheral blood protein indexes and verify its efficacy. The study was divided into...
Eligibility Criteria
Inclusion
- Voluntarily sign informed consent.
- Male or female, age equal to or greater than 18 years and less than 75 years.
- Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection
- The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc.
- Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma.
Exclusion
- Female subjects who are pregnant or breastfeeding.
- Previous organ transplantation or non-autologous bone marrow or stem cell transplantation.
- Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc.
- History of previous malignant tumors.
- Having other malignant tumors or multiple primary tumors at the same time.
Key Trial Info
Start Date :
February 5 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06544083
Start Date
February 5 2024
End Date
February 28 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009